Washington, D.C. 20549






Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) December 28, 2018


(Exact name of registrant as specified in its charter)  


Delaware   000-53012   90-0687379
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)


709 S. Harbor Blvd., Suite 250, Melbourne, FL   32901
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (321) 725-0090


(Former name of former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company       ☐ 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Introductory Comment – Use of Terminology


Throughout this Current Report on Form 8-K, the terms “Company,” “we,” “us,” and “our” refers to First Choice Healthcare Solutions, Inc.  


Section 5 – Corporate Governance and Management


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.


(b) On December 28, 2018, the Company’s Board of Directors notified Chris Romandetti, Sr., the Company’s President and CEO who has been on administrative leave since November 15, 2018, of the termination, effective December 28, 2018, of his March 20, 2014 Employment Agreement with the Company and his employment thereunder for Cause, as defined thereunder, due to material, gross and willful misconduct in connection with his employment duties under the Employment Agreement demonstrated by his actions that provided a basis for a grand jury indictment against him and a Securities and Exchange Commission lawsuit against him.


Mr. Romandetti will only receive accrued but unpaid compensation and vacation pay through the December 28, 2018 date of termination of his Employment Agreement. All options, whether or not vested, held by Mr. Romandetti will immediately expire and all shares of restricted stock for which restrictions have not lapsed will be forfeited effective as of the December 28, 2018 date of termination.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 2, 2019  
  /s/ Phillip J. Keller
  Name: Phillip J. Keller
  Interim Chief Executive Officer and Chief Financial Officer